James Zhao, a managing partner of Vivo Capital, a healthcare investment firm focused on investing in companies in the United States and China, said that the Chinese mobile healthcare sector is good, but investment in the sector has been overheating.

James Zhao, a managing partner of Vivo Capital

"Talent, data accumulation and detailed implementation have not kept pace with the sector's development," Zhao told China Daily.

According to Zhao, requirements of talent in the sector are very high because they need to understand healthcare, the Internet and consumers.

"In my view, we should wait another two to three years before investing in the Chinese mobile healthcare sector," said Zhao.

Zhao said Vivo Capital has invested in 20 healthcare deals in China but none in the mobile healthcare sector.

"We will choose mobile healthcare companies capable of showing business and social value," said Zhao. "Using the collected data to create business and social value is a challenge and also an opportunity."

According to Ouyang, they choose to invest in companies that own good business patterns and can meet the requirements of users.

Legend Capital has invested in 27 healthcare deals at home and abroad totaling $250 million, but only one of them is a mobile healthcare company, Garea, in Jiangsu province.

Mobile health era coming, challenges ahead	Cloud initiative helps promote health service